COVID-19: ICMR issues advisory, asks states to desist from indiscriminate use of Plasma Therapy
New Delhi: The India Council of Medical Research (ICMR) on Wednesday (November 18) mentioned that indiscriminate use of Convalescent Plasma Therapy (CPT) needs to be prevented because it doesn’t scale back mortality in COVID-19 sufferers. Issuing Standard Operating Procedure (SoP), the apex medical analysis physique suggested states to desist from indiscriminate use of plasma remedy.
The ICMR’s new advisory mentioned, “ICMR conducted an open-label phase II multicentre randomised controlled trial in India across 39 public and private hospitals on use of convalescent plasma in the management of cases with moderate COVID-19 disease (PLACID Trial). It was concluded that CPT did not lead to a reduction in progression to severe COVID19 or all cause mortality in the group that received CPT as compared to the group that did not receive CPT.”
It additional mentioned, “PLACID is the world`s largest pragmatic trial on CPT conducted in 464 moderately ill laboratory-confirmed COVID-19 affected adults in real-world setting wherein no benefit of use of CPT could be established.” it mentioned.
The ICMR additionally talked about that related research performed in China and the Netherlands have additionally documented no vital good thing about CPT in enhancing the scientific outcomes of hospitalised COVID-19 sufferers, therefore indiscriminate use of CPT isn’t advisable.
Live TV
“It is speculated that convalescent plasma having a low concentration of specific antibody against SARS-CoV-2 may be less beneficial for treating COVID-19 patients as compared to plasma with a high concentration of such antibodies,” mentioned the steering observe.
The observe additional mentioned, “This ICMR advisory, therefore, embraces the principle that a potential donor for convalescent plasma should have sufficient concentration of antibody working against COVID19,” including {that a} potential donor of CPT generally is a male and female–who have by no means been pregnant can solely donate plasma.
Accordingly, the donor needs to be within the age group of 18-65 years who after 14 days of symptom decision — testing detrimental for COVID-19 isn’t essential, can donate plasma.
For the potential recipient, the ICMR, nevertheless, mentioned that donor may be within the early stage of COVID-19 and the remedy needs to be administered between 3-7 days from onset of signs, however no later than 10 days. There needs to be no IgG antibody towards COVID-19 by acceptable test and knowledgeable consent needs to be taken.
The ICMR observe additional highlighted that presence of antibodies towards COVID-19 in a possible recipient makes transfusing convalescent plasma a futile intervention, including “CPT, therefore, should only be used, as advised by ICMR NTF, for management of COVID-19 when specific criteria are fulfilled.”
The ICMR advisory has been issued within the wake of Union Home Minister Amit Shah’s assembly to evaluate the COVID-19 state of affairs in Delhi, whereby it was mentioned to situation SoP for plasma remedy and plasma administration for therapy of coronavirus sufferers instantly.
(With Agency Inputs)
$(function() { return $("[data-sticky_column]").stick_in_parent({ parent: "[data-sticky_parent]" }); });
reset_scroll = function() { var scroller; scroller = $("body,html"); scroller.stop(true); if ($(window).scrollTop() !== 0) { scroller.animate({ scrollTop: 0 }, "fast"); } return scroller; };
window.scroll_it = function() { var max; max = $(document).height() - $(window).height(); return reset_scroll().animate({ scrollTop: max }, max * 3).delay(100).animate({ scrollTop: 0 }, max * 3); };
window.scroll_it_wobble = function() { var max, third; max = $(document).height() - $(window).height(); third = Math.floor(max / 3); return reset_scroll().animate({ scrollTop: third * 2 }, max * 3).delay(100).animate({ scrollTop: third }, max * 3).delay(100).animate({ scrollTop: max }, max * 3).delay(100).animate({ scrollTop: 0 }, max * 3); };
$(window).on("resize", (function(_this) { return function(e) { return $(document.body).trigger("sticky_kit:recalc"); }; })(this));
}).call(this);
} on_load_google_ad(); function sendAdserverRequest() { try { if (pbjs && pbjs.adserverRequestSent) return; googletag.cmd.push(function() { googletag.pubads().refresh(); }); } catch (e) {
googletag.cmd.push(function() { googletag.pubads().refresh(); }); } } setTimeout(function() { sendAdserverRequest(); }, 5000);
function on_load_fb_twitter_widgets(){ (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.9"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
window.twttr = (function(d, s, id) { var js, fjs = d.getElementsByTagName(s)[0], t = window.twttr || {}; if (d.getElementById(id)) return t; js = d.createElement(s); js.id = id; js.src = "https://platform.twitter.com/widgets.js"; fjs.parentNode.insertBefore(js, fjs); t._e = []; t.ready = function(f) {
t._e.push(f); }; return t; }(document, "script", "twitter-wjs")); }
//setTimeout(function() { on_load_google_ad(); }, 5000); setTimeout(function() { on_load_fb_twitter_widgets(); }, 5000);
Source